Social media

While cardiovascular outcome trials are critical to demonstrating clinical value, they can also be complex and costly. Among the most challenging aspects are the people involved, from patients to investigators and commit...

Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp...

The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. In the latest blog in our managing risk for medical devices series...

Our Creative & Digital Services and Global Medical Communications teams have been honoured for the ISMPP Academy Poster with an Rx Club Award of Excellence in the Posters/Display category. Congratulations for delivering ...

There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford...

2025 has seen both the EMA and the FDA publish new position papers and opinions on streamlining the trial process for biosimilars. On the surface, reducing reliance on comparative efficacy trials has the potential to sav...

Do you know the difference between decision trees and random forests? Learn about AI models for SaMDs in our new whitepaper. Download it now to learn best practices for model and data selection. https://ow.ly/nI8g50XAzbq

For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase...

Yao Zhong's career in clinical development spans two decades and multiple leadership roles across the industry. When the opportunity came to return to ICON and lead our newly integrated China business, he recognised the ...

Zhong Yao's career in clinical development spans two decades and multiple leadership roles across the industry. When the opportunity came to return to ICON and lead our newly integrated China business, he recognised the ...

In a fast-moving market like healthcare, speed matters. Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts wi...

How do you go from a meaningful aspect of health to a validated endpoint? Download our whitepaper for a step-by-step guide on a structured approach to deploying digital endpoints: 1. Define the Concept of Interest 2. Id...